AC Immune SA
$2.98
▼
-1.08%
2026-04-21 05:03:00
www.acimmune.com
NGM: ACIU
Explore AC Immune SA stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$303.29 M
Current Price
$2.98
52W High / Low
$4 / $1.45
Stock P/E
—
Book Value
$0.56
Dividend Yield
—
ROCE
-115.62%
ROE
-89.65%
Face Value
—
EPS
$-0.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
90
Beta
1.63
Debt / Equity
10.12
Current Ratio
1.02
Quick Ratio
1.02
Forward P/E
5.36
Price / Sales
93.43
Enterprise Value
$238.51 M
EV / EBITDA
-3.54
EV / Revenue
66.75
Rating
Strong Buy
Target Price
$9.05
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Harmony Biosciences Holdings, Inc. | $29.53 | 10.93 | $1.73 B | — | 20.45% | 20.75% | $40.87 / $25.52 | $15.07 |
| 2. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 3. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
| 4. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
| 5. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 6. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 7. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.34 M | 0.94 M | 1.31 M | 0.99 M | 1.14 M | — |
| Operating Profit | -14.41 M | -15.7 M | -19.39 M | -19.37 M | -18.62 M | — |
| Net Profit | -14.37 M | -15.86 M | -21.19 M | -19.03 M | -15.8 M | — |
| EPS in Rs | -0.14 | -0.16 | -0.21 | -0.19 | -0.16 | 0.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.57 M | 27.31 M | 14.8 M | 3.94 M |
| Operating Profit | -68.86 M | -52.38 M | -53.62 M | -70.85 M |
| Net Profit | -70.45 M | -50.92 M | -54.23 M | -70.75 M |
| EPS in Rs | -0.69 | -0.5 | -0.53 | -0.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 154.25 M | 230.91 M | 182.81 M | 185.94 M |
| Total Liabilities | 109.37 M | 118.64 M | 22.17 M | 16.95 M |
| Equity | 44.88 M | 112.27 M | 160.64 M | 168.99 M |
| Current Assets | 96.72 M | 171.99 M | 125.15 M | 128.09 M |
| Current Liabilities | 94.69 M | 100.84 M | 13.58 M | 11.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -69.26 M | 65.84 M | -60.41 M | -73.57 M |
| Investing CF | 63.54 M | -105.29 M | 65.64 M | 23.76 M |
| Financing CF | -1.02 M | -1.12 M | 43.25 M | -1.35 M |
| Free CF | -70.16 M | 65.27 M | -61.21 M | -74.81 M |
| Capex | -0.9 M | -0.58 M | -0.8 M | -1.24 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -86.92% | 84.51% | 276.14% | — |
| Earnings Growth % | -38.36% | 6.12% | 23.35% | — |
| Profit Margin % | -1971.65% | -186.44% | -366.41% | -1798.04% |
| Operating Margin % | -1927.32% | -191.8% | -362.3% | -1800.43% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1896.25% | -178.03% | -350.19% | -1728.74% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.